Ezrin调控肝癌细胞侵袭性伪足的形成促进肝细胞癌侵袭转移

郑博文; 王保林; 路遥; 黄登; 张航; 刘嘉龙; 郑树国

doi:10.16016/j.2097-0927.202111088

您当前的位置：

首页 >

文章列表页 >

Ezrin调控肝癌细胞侵袭性伪足的形成促进肝细胞癌侵袭转移

基础医学 | 更新时间：2026-01-09

- Ezrin调控肝癌细胞侵袭性伪足的形成促进肝细胞癌侵袭转移
- Ezrin promotes invasion and metastasis of hepatocellular carcinoma by regulating invadopodia formation
- 陆军军医大学学报 2022年44卷第4期页码：346-355
- 作者机构：
  
  1.400038 重庆，陆军军医大学(第三军医大学)第一附属医院全军肝胆外科研究所
  2.850032 拉萨，中国人民解放军西藏军区总医院肝胆科
- 作者简介：
  
  [郑树国，E-mail: shuguozh@163.com ZHENG Shuguo, E-mail: shuguozh@163.com
- 基金信息：
  
  国家自然科学基金面上项目(81972303)
- DOI：10.16016/j.2097-0927.202111088
  中图分类号： R394.3;R730.23;R735.7
- 收稿：2021-11-11，
  
  修回：2021-12-01，
  
  纸质出版：2022-02-28
- 稿件说明：
移动端阅览
郑博文, 王保林, 路遥, 等. Ezrin调控肝癌细胞侵袭性伪足的形成促进肝细胞癌侵袭转移[J]. 陆军军医大学学报, 2022,44(4):346-355.

Bowen ZHENG, Baolin WANG, Yao LU, et al. Ezrin promotes invasion and metastasis of hepatocellular carcinoma by regulating invadopodia formation[J]. Journal of Army Medical University, 2022, 44(4): 346-355.
郑博文, 王保林, 路遥, 等. Ezrin调控肝癌细胞侵袭性伪足的形成促进肝细胞癌侵袭转移[J]. 陆军军医大学学报, 2022,44(4):346-355. DOI： 10.16016/j.2097-0927.202111088.

Bowen ZHENG, Baolin WANG, Yao LU, et al. Ezrin promotes invasion and metastasis of hepatocellular carcinoma by regulating invadopodia formation[J]. Journal of Army Medical University, 2022, 44(4): 346-355. DOI： 10.16016/j.2097-0927.202111088.

摘要

目的

探讨Ezrin在肝癌细胞侵袭性伪足形成过程中的作用。

方法

利用GEPIA数据库分析肝癌组织中Ezrin mRNA与伪足标志物Cortactin mRNA的表达相关性。将收集的105例肝细胞癌患者的组织标本制作成组织芯片，采用免疫组化检测Ezrin蛋白和伪足标志物Cortactin蛋白在肝癌组织中的表达，并分析二者的表达相关性。分析Ezrin的表达水平与肝癌患者临床病理特征及预后的关系。敲低和上调肝癌细胞中Ezrin的表达，采用Transwell实验观察Ezrin蛋白的表达变化对肝癌细胞侵袭迁移能力的影响，采用Western blot和细胞免疫荧光技术检测Ezrin蛋白表达变化对肝癌细胞侵袭性伪足形成能力的影响。

结果

生物信息学分析结果提示肝癌组织中Ezrin mRNA与伪足标志物Cortactin mRNA的表达呈正相关(

=0.420，

＜0.01)。肝癌组织芯片免疫组化结果显示Ezrin蛋白与伪足标志物Cortactin蛋白的表达水平呈正相关(

=0.491，

＜0.001)。患者临床资料结果显示，Ezrin蛋白的高表达与肝癌患者的血管侵犯率(

=0.016)及肿瘤相关死亡率(

=0.018)相关，且Ezrin蛋白高表达患者的术后5年生存率及术后5年无瘤生存率均较低(

＜0.05)。细胞实验结果显示，上调Ezrin蛋白的表达可促进肝癌细胞的侵袭和迁移(

＜0.05)，且其高表达可促进肝癌细胞侵袭性伪足的形成(

＜0.05)；敲低Ezrin蛋白表达可抑制肝癌细胞侵袭性伪足的形成，并降低肝癌细胞的侵袭和迁移能力。

结论

Ezrin可通过调控肝癌细胞侵袭性伪足的形成增强肝癌细胞的侵袭、迁移能力，进而促进肝癌进展。

Abstract

Objective

To explore the role of ezrin in the formation of invadopodia in hepatocellular carcinoma (HCC) cells.

Methods

GEPIA database was used to analyze the expression correlation between ezrin and the invadopodia marker cortactin in HCC tissues at mRNA level. Tissue specimens obtained from 105 HCC patients were made into tissue microarrays

which were subsequently detected by immunohistochemistry to analyze the expression correlation of ezrin with cortactin at protein level. Moreover

the relationship between ezrin level and the clinicopathological features as well as the prognosis of HCC patients were analyzed. Finally

ezrin expression was knocked down or up-regulated in HCC cells

respectively

and Transwell assay was performed to observe the effects of ezrin expression changes on the invasion and migration of HCC cells; Western blotting and immunofluorescence assay were also adopted to detect the role of ezrin in the formation of invadopodia in HCC cells.

Results

Bioinformatics analysis revealed that the mRNA level of ezrin was positively correlated with that of cortactin in HCC tissues (

=0.420

0.01)

and immunohistochemistry assay also confirmed the positive correlation between ezrin and cortactin expression at protein level (

= 0.491

0.001). Analysis of clinical data showed that high expression of ezrin protein was correlated with vascular invasion rate (

=0.016) and tumor-related mortality rate (

=0.018) in HCC patients

and pati

ents with higher ezrin level had both lower 5-year postoperative survival rate and 5-year tumor-free survival rate (

0.05). In cell experiments

up-regulation of ezrin promoted the invasion and metastasis (

0.05)

and facilitated the invadopodia formation of HCC cells (

0.05). In contrast

knockdown of ezrin suppressed the invadopodia formation and inhibited the invasion and metastasis of HCC cells.

Conclusion

Ezrin enhances the invasive and migratory abilities of HCC cells by regulating invadopodia formation and thus promotes the progression of HCC.

关键词

Keywords

references

YANG J D, HAINAUT P, GORES G J, et al . A global view of hepatocellular carcinoma: trends, risk, prevention and management[J ] . Nat Rev Gastroenterol Hepatol, 20 19, 16(10): 589-604. DOI: 10.1038/s41575-019-0186-y.

LUO P, WU S, YU Y, et al . Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage[J ] . Pathol Oncol Res, 2020, 26(2): 599-603. DOI: 10.1007/s12253-019-00585-5.

PAZ H, PATHAK N, YANG J. Invading one step at a time: the role of invadopodia in tumor metastasis[J]. Oncogene, 2014, 33(33): 4193-4202. DOI: 10.1038/onc.2013.393.

MD HASHIM N F, NICHOLAS N S, DART A E, et al . Hypoxia-inducedinvadopodia formation: a role for β-PIX[J ] . Open Biol, 2013, 3(6): 120159. DOI: 10.1098/rsob.120159.

CHEN Z C, HE S M, ZHAN Y H, et al . TGF-β-induced transgelin promotes bladder cancer metastasis by regulating epithelial-mesenchymal transition and invadopodia formation[J ] . EBioMedicine, 2019, 47: 208-220. DOI: 10.1016/j.ebiom.2019.08.012.

PENG X, LI X, YANG S, et al . LINC00511 drives invasive behavior in hepatocellular carcinoma by regulating exosome secretion and invadopodia formation[J ] . J Exp Clin Cancer Res, 2021, 40(1): 183. DOI: 10.1186/s13046-021-01990-y.

JERRELL R J, PAREKH A. Matrix rigidity differentially regulates invadopodia activity through ROCK1 and ROCK2[J]. Biomaterials, 2016, 84: 119-129. DOI: 10.1016/j.biomaterials.2016.01.028.

PATERSON E K, COURTNEIDGE S A. Invadosomes are coming: new insights into function and disease relevance[J]. Febs J, 2018, 285(1): 8-27. DOI: 10.1111/febs.14123.

ZHAO G, HUANG Z M, KONG Y L, et al . Cortactin is a sensitive biomarker relative to the poor prognosis of human hepatocellular carcinoma[J ] . World J Surg Oncol, 2013, 11: 74. DOI: 10.1186/1477-7819-11-74.

JIN Y, LIANG Z Y, ZHOU W X, et al . High MMP14 expression is predictive of poor prognosis inresectable hepatocellular carcinoma[J ] . Pathology, 2020, 52(3): 359-365. DOI: 10.1016/j.pathol.2020.01.436.

KAWAGUCHI K, YOSHIDA S, HATANO R, et al . Pathophysiological roles of Ezrin/Radixin/Moesin proteins[J ] . Biol Pharm Bull, 2017, 40(4): 381-390. DOI: 10.1248/bpb.b16-01011.

BAKHEET A M H, MAHMOUD S A, HUANG Y H, et al . Ezrin as a possible diagnostic and/or prognostic biomarker in mice lymphatic metastatic hepatocellular carcinoma in vivo [J ] . Biofactors, 2017, 43(5): 662-672. DOI: 10.1002/biof.1368..

PAN D B, WANG S, YE H L, et al . Ezrin expression in the primary hepatocellular carcinoma patients and associated with clinical, pathological characteristics[J ] . J Cancer Res Ther, 2016, 12(Supplement): C291-C294. DOI: 10.4103/0973-1482.200761.

XUE Y H, BHUSHAN B, MARS W M, et al . Phosphorylated ezrin (Thr567) regulates hippo pathway and Yes-Associated Protein (Yap) in liver[J ] . Am J Pathol, 2020, 190(7): 1427-1437. DOI: 10.1016/j.ajpath.2020.03.014.

CHEN Y, WANG D, GUO Z, et al . Rho kinase phosphorylation promotesezrin-mediated metastasis in hepatocellular carcinoma[J ] . Cancer Res, 2011, 71(5): 1721-1729. DOI: 10.1158/0008-5472.can-09-4683.

林晶, 沈海洋, 王丽虹. 埃兹蛋白与肝癌侵袭转移及上皮间质转化的关系[J]. 实用肿瘤学杂志, 2012, 26 (6): 524-527. DOI: 10.3969/j.issn.1002-3070.2012.06.010.

LIN J, SHEN H Y, WANG L H. The role played by Ezrin in hepatocellular carcinoma, as well as the relationship between ezrin and epithelial mesenchumal transition[J]. Prac Oncol J, 2012, 26(6): 524-527. DOI: 10.3969/j.issn.1002-3070.2012.06.010.

YAMAGUCHI H. Pathological roles of invadopodia in cancer invasion and metastasis[J]. Eur J Cell Biol, 2012, 91(11/12): 902-907. DOI: 10.1016/j.ejcb.2012.04.005.

MURPHY D A, COURTNEIDGE S A. The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function[J]. Nat Rev Mol Cell Biol, 2011, 12(7): 413-426. DOI: 10.1038/nrm3141.

LEHTIMÄKI J, HAKALA M, LAPPALAINEN P. Actin filament structures in migrating cells[J]. Handb Exp Pharmacol, 2017, 235: 123-152. DOI: 10.1007/164_2016_28.

LIU P, YANG P, ZHANG Z, et al . Ezrin/NF-κB pathway regulates EGF-induced epithelial-mesenchymal transition (EMT), metastasis, and progression of osteosarcoma[J ] . Med Sci Monit, 2018, 24: 2098-2108. DOI: 10.12659/msm.906945.

HOSKIN V, SZETO A, GHAFFARI A, et al . Ezrin regulates focal adhesion and invadopodia dynamics by altering calpain activity to promote breast cancer cell invasion[J ] . Mol Biol Cell, 2015, 26(19): 3464-3479. DOI: 10.1091/mbc.e14-12-1584.

ANTELMI E, CARDONE R A, GRECO M R, et al . β1 integrin binding phosphorylates ezrin at T567 to activate a lipid raft signalsome driving invadopodia activity and invasion[J ] . PLoS One, 2013, 8(9): e75113. DOI: 10.1371/journal.pone.0075113.

WANG X, LI N, HAN A, et al . Ezrin promotes hepatocellular carcinoma progression by modulating glycolytic reprogramming[J ] . Cancer Sci, 2020, 111(11): 4061-4074. DOI: 10.1111/cas.14562.

WEAVER A M. Cortactin in tumor invasiveness[J]. Cancer Lett, 2008, 265(2): 157-166. DOI: 10.1016/j.canlet.2008.02.066.

ZHAO G, ZHANG H Y, HUANG Z M, et al . Cortactin and Exo70 mediated invasion of hepatoma carcinoma cells by MMP-9 secretion[J ] . Mol Biol Rep, 2016, 43(5): 407-414. DOI: 10.1007/s11033-016-3972-4.

CRIMALDI L, COURTNEIDGE S A, GIMONA M. Tks5 recruits AFAP-110, p190RhoGAP, and cortactin for podosome formation[J]. Exp Cell Res, 2009, 315(15): 2581-2592. DOI: 10.1016/j.yexcr.2009.06.012.

OSER M, YAMAGUCHI H, MADER C C, et al . Cortactin regulates cofilin and N-WASp activities to control the stages of invadopodium assembly and maturation[J ] . J Cell Biol, 2009, 186(4): 571-587. DOI: 10.1083/jcb.200812176.

CLARK E S, WHIGHAM A S, YARBROUGH W G, et al . Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation ininva dopodia[J ] . Cancer Res, 2007, 67(9): 4227-4235. DOI: 10.1158/0008-5472.can-06-3928.

SONG Y, MA X, ZHANG M, et al . Ezrin mediates invasion and metastasis in tumorigenesis: a review[J ] . Front Cell Dev Biol, 2020, 8: 588801. DOI: 10.3389/fcell.2020.588801.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

SLC38A1通过促进谷氨酰胺摄取激活PI3K/AKT信号通路驱动肝细胞癌恶性进展

肝细胞癌临床诊治新进展：综合治疗策略的演变

程序性死亡配体-1通过抑制蛋白酪氨酸磷酸酶1B激活黏着斑激酶促进肝细胞癌进展

核表皮生长因子受体与转录因子YY1协同驱动CEMIP表达促进肝细胞癌侵袭

谷胱甘肽过氧化物酶7通过PI3K-AKT通路调控肝癌细胞增殖和衰老